HSG 4113
Alternative Names: HSG4113Latest Information Update: 28 Dec 2023
At a glance
- Originator Glaceum
- Class Antihyperglycaemics; Insulin sensitisers; Obesity therapies; Small molecules
- Mechanism of Action Insulin receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Obesity
Highest Development Phases
- No development reported Obesity; Type 2 diabetes mellitus
Most Recent Events
- 28 Dec 2023 No recent reports of development identified for preclinical development in Obesity in South Korea (PO)
- 28 Nov 2023 No recent reports of development identified for preclinical development in Type-2-diabetes-mellitus in South Korea (PO)
- 02 Mar 2020 HSG 4113 is available for licensing as of 02 Mar 2020. http://en.glaceum.com/